The gene encoding IL-1 was sequenced more than 30 years ago, and many related cytokines, such as IL-18, IL-33, IL-36, IL-37, IL-38, IL-1 receptor antagonist (IL-1Ra), and IL-36Ra, have since been identified. IL-1 is a potent proinflammatory cytokine and is involved in various inflammatory diseases. Other IL-1 family ligands are critical for the development of diverse diseases, including inflammatory and allergic diseases. Only IL-1Ra possesses the leader peptide required for secretion from cells, and many ligands require posttranslational processing for activation. Some require inflammasome-mediated processing for activation and release, whereas others serve as alarmins and are released following cell membrane rupture, for example, by pyroptosis or necroptosis. Thus, each ligand has the proper molecular process to exert its own biological functions. In this review, we will give a brief introduction to the IL-1 family cytokines and discuss their pivotal roles in the development of various liver diseases in association with immune responses. For example, an excess of IL-33 causes liver fibrosis in mice via activation and expansion of group 2 innate lymphoid cells to produce type 2 cytokines, resulting in cell conversion into pro-fibrotic M2 macrophages. Finally, we will discuss the importance of IL-1 family cytokine-mediated molecular and cellular networks in the development of acute and chronic liver diseases.

1. Introduction

The supernatants of activated leukocytes were shown to have the capacity to activate lymphocytes in the 1940s [1]. In 1979, four decades later, the active molecule was designated as interleukin- (IL-) 1. In 1984, the cDNA for murine IL-1 was identified. IL-1 is composed of two different molecules, IL-1α and IL-1β, which are recognized by the same receptor (R), known as the IL-1 receptor, which consists of IL-1R1 and IL-1RAcP [1]. Both IL-1α and IL-1β play roles in innate immunity. Subsequently, a third molecule, IL-1R antagonist (IL-1Ra), was discovered [2]. IL-1Ra competitively binds to IL-1R1 but does not have the capacity to activate IL-1 signaling. In 1995, another member of the IL-1 family, interferon-γ inducing factor (IGIF), was identified [3]. Due to its homology with IL-1α and IL-1β and to the similarity of its mode of production to that of IL-1β, IGIF was temporarily called “IL-ly” [4]. Indeed, like IL-1β, IGIF lacks a leader peptide and is produced as a biologically inactive precursor (pro). Pro-IGIF, like pro-IL-1β, requires posttranslational processing for activation and secretion [5]. However, IGIF has been shown to require IL-18R but not IL-1R for signaling transduction; neither IL-1α nor IL-1β requires IL-18R [6]. This indicates that IGIF is a member of the IL-1 family but not of IL-1 itself. Thus, IGIF was designated as IL-18. IL-18 is a unique cytokine that activates both innate and acquired immunity, including both Th1 and Th2 immune responses, and has important pathophysiological functions. In 2005, another member of the IL-1 family, IL-33, was identified [7]. Unlike IL-1 or IL-18, IL-33 is important for the development of the type 2 immune response and several diseases. Subsequently, several proteins that show homology with IL-1 family members but have different biological functions have been discovered, such as IL-36α, IL-36β, IL-36γ, IL-36Ra, IL-37, and IL-38 [8]. In this review, we will focus on the roles of IL-1, IL-18, and IL-33 in various liver diseases, following a brief introduction to the IL-1 family, with the aim of clarifying the molecular and cellular networks involving each cytokine that are activated in liver diseases. We will focus on the unique mechanism of liberation of each cytokine and on the liver resident cells that may release and respond to each cytokine. Many excellent reviews have been published that can provide the reader with recent, detailed histological findings on the members of the IL-1 family [9–11].
2 Mediators of Inflammation

IL-33
IL-18 subfamily

IL-1α
IL-1β
IL-33
IL-18
IL-37
IL-36
IL-38
IL-1 subfamily

IL-18 subfamily

IL-1Ra
IL-1R2
IL-36Ra
IL-38
IL-18Rα
IL-18Rβ
IL-36R
IL-36Ra
IL-36γ
IL-36β
IL-36α
IL-1Ra
IL-18Rα
IL-18Rβ
SIGIRR (TIR8)

MyD88

NF-κB

MAPKs

Figure 1: IL-1 family agonists and antagonists. The IL-1 family is divided into three subfamilies based on the length of the N-terminal pro-pieces. The IL-1 subfamily consists of IL-1α, IL-1β, IL-1 receptor antagonist (IL-1Ra), and IL-33. The IL-18 subfamily is composed of IL-18 and IL-37. IL-36α, IL-36β, IL-36γ, and IL-38 belong to the IL-36 subfamily. The receptor for each IL-1 family cytokine is a heterodimer of the proper or common subunits. IL-1R1, ST2, IL-18Rα, and IL-36R are ligand-binding subunits, whereas IL-1R accessory protein (IL-1RAcP), IL-18Rβ, and SIGIRR (TIR8) are signaling subunits. Upon engagement of the binding subunits with the corresponding ligands, they recruit the corresponding signaling receptor subunit, which, except in IL-37 signaling, ultimately translocates nuclear factor- (NF-)κB to the nucleus and activates MAPKs such as p38 and JNK. IL-38, IL-1Ra, IL-18-binding protein (IL-18BP), and IL-36Ra inhibit IL-36, IL-1, IL-18, and IL-36 signaling, respectively. IL-37 inhibits the signal pathways of the innate and acquired immune responses via mechanisms that are poorly identified. IL-1R2 acts as a decoy receptor for IL-1α and IL-1β. Stop signs indicate proteins that inhibit corresponding ligand signaling or those that negatively regulate other signal pathways as well. JNK: c-jun-N-terminal kinase; MAPK: mitogen-activated protein kinase; SIGIRR: single immunoglobulin IL-1-related receptor; ST2: suppression of tumorigenicity 2.

2. The IL-1 and IL-1R Families

The IL-1 family ligands and the corresponding receptor subunits are shown in Figure 1. All of the receptor subunits are members of the IL-1R family and are characterized by possession of a Toll-like receptor (TLR)/IL-1R (TIR) domain within their cytoplasmic tails. TIR is required by IL-1 family members and TLR ligands for signaling. IL-1 family ligands comprise seven members with agonistic functions (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, and IL-36γ) and four members with antagonistic activities, such as IL-1Ra, IL-36Ra, IL-37, and IL-38. IL-1R family members include four ligand-binding subunits, IL-1R1, ST2, IL-18Rα, and IL-36R, and three signaling subunits, IL-1RAcP, IL-18Rβ, and single immunoglobulin IL-1-related receptor (SIGIRR), alternatively named TIR8. SIGIRR/TIR8 is regarded as an orphan receptor with regulatory functions [12].

IL-1 family ligands are classified into three groups, based on the size of the N-terminal pro-pieces that remain after cleavage of the full-length ligands [9–11]. Members of the IL-1 subfamily, such as IL-1α, IL-1β, and IL-33, possess the longest pro-pieces, composed of approximately 270 amino acids.

Both IL-1α and IL-1β transduce signals via IL-1R, a heterodimer of IL-1R1 and IL-1RAcP. IL-33 uses ST2 and IL-1RAcP. IL-18 subfamily ligands, including IL-18 and IL-37, also possess long pro-pieces composed of approximately 190 amino acids. The receptor for IL-18 consists of a binding subunit, IL-18Rα, and a signaling chain, IL-18Rβ. IL-37 binds to IL-18Rα, and SIGIRR (TIR8) is required as the signaling subunit. Notably, the mouse homologue of IL-37 remains unknown. IL-36 subfamily ligands such as IL-36α, IL-36β, IL-36γ, and IL-38 possess small pro-pieces of approximately 150 amino acids. All except IL-38 bind to IL-36R, followed by signaling via the coreceptor, IL-1RAcP.

The biological functions of IL-1 (IL-1α and IL-1β) and IL-36 (IL-36α, IL-36β, and IL-36γ) are negatively regulated by IL-1Ra and IL-36Ra, respectively. IL-1Ra, in competition with IL-1α and IL-1β, binds to IL-1R1, but unlike the IL-1α/IL-1R1 or IL-1β/IL-R1 complexes, the IL-1Ra/IL-1R1 complex cannot recruit the signaling chain, IL-1RAcP, eventually resulting in inhibition of IL-1 signaling [13]. Similarly, IL-36Ra binds to IL-36R and inhibits recruitment of the IL-36 signaling receptor chain, IL-1RAcP, onto IL-36R [14]. IL-1R2 is a “decoy receptor” that competitively inhibits IL-1α/β binding to...
IL-1R1. IL-18-binding protein (IL-18BP), which does not belong to the IL-1 family, is a natural inhibitor of IL-18 [15].

Following binding of a ligand to its corresponding binding receptor subunit, the ligand/binding receptor subunit complex recruits the corresponding signaling subunit. In this setting, the cytoplasmic tails of the binding and signaling subunits can recruit and interact with the signaling adaptor molecule MyD88 via TIR-TIR interaction, which eventually results in the nuclear translocation of nuclear factor-κB (NF-κB) and the activation of mitogen-activated protein kinases (MAPKs) such as p38 and c-Jun-N-terminal kinase (JNK) [14, 16, 17] (Figure 1).

3. Modes of Liberation of Biologically Active Ligands

Because they lack leader peptides, none of the members of the IL-1 family, except IL-1Ra, are extracellularly released immediately after translation. The full-length cytokines remain inside the cell, unless the cell is appropriately stimulated or damaged. Some full-length ligands, such as IL-33 and IL-1α, are biologically active but require cellular damage for release [18–20] (Figure 2 right). Full-length IL-1α is biologically active, but processed IL-1α has been reported to exert higher activity than full-length IL-1α [21, 22]. Full-length IL-1α and IL-33 are not released unless the cellular membrane is destroyed. Thus, IL-1α and IL-33 are designated as alarmins.

Some of the IL-1 family members are produced as biologically inactive precursor proteins and require appropriate posttranslational processing for activation and release from cells, such as IL-1β, IL-18, IL-37, IL-36α, IL-36β, IL-36γ, and IL-36Ra. IL-1β, IL-18, and IL-37 are processed by caspase-1, which was initially termed IL-1β-converting enzyme (ICE) [5, 18, 23–25] (Figure 2 left). In contrast, IL-36 subfamily members commonly lack caspase-1 cleavage sites. Their processing enzymes remain to be identified [14].

Caspase-1 is a member of the caspase family [26]. Caspase family members are produced as enzymatically inactive zymogens. Based on function, caspases have been classified into two groups, cell death-associated caspases (caspase-8, caspase-9, caspase-6, caspase-7, and caspase-3) and inflammatory caspases (caspase-1, caspase-4, caspase-5, and caspase-11). The activation cascade of the cell death-associated caspases was identified in the 1990s. However, the molecular mechanism for the activation of inflammatory caspases remained enigmatic until 2002. The late Dr. J. Tschopp proposed that a large protein complex, named the inflammasome, was the cytoplasmic machinery that activates caspase-1 for release of resultant mature IL-1β and IL-18 [27]. Several types of inflammasomes, with different cytoplasmic sensors, such as NACHT, leucine-rich repeat (LRR), and pyrin...
domain- (PYD-) containing protein- (NLRP-) 1 (NLRP1), NLRP3, caspase recruitment domain- (CARD-) containing protein- (NLRC-) 4 (NLRC4), and absent in melanoma 2 (AIM2) have since been identified (Figure 3 upper). Those proteins are cytoplasmic pattern recognition receptors (PRRs) that sense extrinsic pathogen-associated molecular patterns (PAMPs) and intrinsic damage-associated molecular patterns (DAMPs). Three of the proteins, NLRP1, NLRP3, and NLRC4, belong to the Nod-like receptor (NLR) family. AIM2 is a cytoplasmic DNA sensor that does not belong to the NLR family. When cells such as neutrophils, macrophages, or dendritic cells are appropriately stimulated [28], one of these sensors, a caspase-1 adaptor protein named apoptosis-associated speck-like protein containing a carboxy-terminal CARD (ASC) and procaspase-1, begins to assemble to form the inflammasome [29–33]. Structural analysis has revealed that, in some inflammasomes, such as NLRP3 and AIM2 inflammasomes, many procaspase-1 proteins likely polymerize to form a filamentous structure that permits autocleavage of procaspase-1 [34]. We found that the NLRP3 inflammasome is essential for the elevated serum levels of IL-18 observed in heat-killed \textit{Propionibacterium acnes}-primed mice after challenge with lipopolysaccharide (LPS) [35]. Intriguingly, deletion of the genes encoding either component of the NLRP3 inflammasome or the resulting IL-18 prevented LPS-induced liver injury in \textit{P. acnes}-primed mice. Indeed, \textit{Nlrp3}−/−, \textit{Asc}−/−, \textit{Caspase1}−/−, and \textit{Il18}−/− mice are resistant to liver injury induced by sequential treatment with \textit{P. acnes} and LPS [3, 35, 36]. Recently, it was shown that IL-37 requires the NLRP3 inflammasome for activation and nuclear translocation [24]. In addition, several different types of noncanonical inflammasomes have been demonstrated to be required for activation of the canonical inflammasomes. For example, the caspase-11 noncanonical inflammasome was demonstrated to be essential for the activation of the canonical NLRP3 inflammasome in macrophages after Gram-negative bacterial infection [37–39]. Notably, ES cells derived from mouse strain 129 express little caspase-11, and the \textit{Caspase11}−/− mice currently used worldwide were generated from ES cells expressing \textit{Caspase11}129/129. Even after heavy backcrossing with C57BL/6 (B6) mice, \textit{Caspase1}−/− B6 mice still possess \textit{Caspase11}129/129, because of the close proximity of \textit{Caspase1} and \textit{Caspase11}. Therefore, data obtained using these \textit{Caspase1}−/− \textit{Caspase11}129/129 mice are equivalent to data for \textit{Caspase1}−/− \textit{Caspase11}−/− mice. Before the function of endogenous caspase-1 could be determined, B6 ES cell-derived \textit{Caspase1}−/− mice had to be developed. Previous to

Figure 3: Processing enzymes dependent on and independent of the inflammasome. Caspase-1 is an enzyme that putatively converts IL-1β and IL-18. Caspase-1 is produced aszymogen and requires cleavage. Inflammasomes are the machinery in which caspase-1, IL-1β, and IL-18 are processed. Inflammasomes are classified as canonical and noncanonical. Canonical inflammasomes can be divided into 4 main types based on differences in cytoplasmic PRRs, such as NLRP1, NLRP3, NLRC4, and AIM. Noncanonical inflammasomes activate caspase-11, caspase-8, caspase-4, and caspase-5 and often collaborate with the canonical inflammasomes. Monocyte-macrophage lineage cells, dendritic cells, and neutrophils can harbor inflammasomes. Various enzymes have the capacity to process IL-1β and IL-18 extracellularly. Neutrophil-derived proteinase 3, mast cell chymase, granzyme B produced by NK cells, and meprins produced by epithelial cells can convert pro-IL-1β and pro-IL-18 into mature ligands. AIM: absent in melanoma 2; NK: natural killer; NLRC: NACHT, leucine-rich repeat, and caspase-recruitment domain-containing protein; NLR: NACHT, leucine-rich repeat, and pyrin domain-containing protein; PRR: pattern recognition receptor.

Domain- (PYD-) containing protein- (NLRP-) 1 (NLRP1), NLRP3, caspase recruitment domain- (CARD-) containing protein- (NLRC-) 4 (NLRC4), and absent in melanoma 2 (AIM2) have since been identified (Figure 3 upper). Those proteins are cytoplasmic pattern recognition receptors (PRRs) that sense extrinsic pathogen-associated molecular patterns (PAMPs) and intrinsic damage-associated molecular patterns (DAMPs). Three of the proteins, NLRP1, NLRP3, and NLRC4, belong to the Nod-like receptor (NLR) family. AIM2 is a cytoplasmic DNA sensor that does not belong to the NLR family. When cells such as neutrophils, macrophages, or dendritic cells are appropriately stimulated [28], one of these sensors, a caspase-1 adaptor protein named apoptosis-associated speck-like protein containing a carboxy-terminal CARD (ASC) and procaspase-1, begins to assemble to form the inflammasome [29–33]. Structural analysis has revealed that, in some inflammasomes, such as NLRP3 and AIM2 inflammasomes, many procaspase-1 proteins likely polymerize to form a filamentous structure that permits autocleavage of procaspase-1 [34]. We found that the NLRP3 inflammasome is essential for the elevated serum levels of IL-18 observed in heat-killed \textit{Propionibacterium acnes}-primed mice after challenge with lipopolysaccharide (LPS) [35]. Intriguingly, deletion of the genes encoding either component of the NLRP3 inflammasome or the resulting IL-18 prevented LPS-induced liver injury in \textit{P. acnes}-primed mice. Indeed, \textit{Nlrp3}−/−, \textit{Asc}−/−, \textit{Caspase1}−/−, and \textit{Il18}−/− mice are resistant to liver injury induced by sequential treatment with \textit{P. acnes} and LPS [3, 35, 36]. Recently, it was shown that IL-37 requires the NLRP3 inflammasome for activation and nuclear translocation [24]. In addition, several different types of noncanonical inflammasomes have been demonstrated to be required for activation of the canonical inflammasomes. For example, the caspase-11 noncanonical inflammasome was demonstrated to be essential for the activation of the canonical NLRP3 inflammasome in macrophages after Gram-negative bacterial infection [37–39]. Notably, ES cells derived from mouse strain 129 express little caspase-11, and the \textit{Caspase11}−/− mice currently used worldwide were generated from ES cells expressing \textit{Caspase11}129/129. Even after heavy backcrossing with C57BL/6 (B6) mice, \textit{Caspase1}−/− B6 mice still possess \textit{Caspase11}129/129, because of the close proximity of \textit{Caspase1} and \textit{Caspase11}. Therefore, data obtained using these \textit{Caspase1}−/− \textit{Caspase11}129/129 mice are equivalent to data for \textit{Caspase1}−/− \textit{Caspase11}−/− mice. Before the function of endogenous caspase-1 could be determined, B6 ES cell-derived \textit{Caspase1}−/− mice had to be developed. Previous to
Mediators of Inflammation

4. Extracellular Processing of Precursor Cytokines

Precursor cytokines can be activated by machinery other than inflammasomes. Many enzymes other than caspases can cleave pro-IL-1β and pro-IL-18 into biologically active fragments (Figure 3 lower).

Serine proteases can process IL-1β and IL-18. Neutrophils possess several types of serine proteases in their azurophilic granules. Neutrophil elastase, proteinase 3 (PR3), and cathepsin G are representative of neutrophil serine proteases [58, 59]. Purified PR3 activates the human Mo cell line THP-1 to release IL-1β independent of caspase-1 [60]. The importance of PR3-mediated IL-1β processing has also been demonstrated in vivo. WT mice, but not IL1β−/− mice, developed chronic arthritis after multiple intra-articular challenges with streptococcal cell wall. Dppi−/− mice, which lack the ability to activate PR3, are partly resistant to this chronic arthritis and show reduced induction of biologically active IL-1β in synovial explants, whereas Caspase1−/− mice are similarly susceptible to WT mice [61]. The importance of PR3-mediated IL-1β processing has also been demonstrated in peritonitis induced by intraperitoneal challenge with monosodium urate crystals, a self-derived molecule relevant to gout [62]. Thus, multiple IL-1β-converting enzymes, including PR3, are required for inflammatory arthritis in mice [63]. PR3 is also involved in the processing of IL-18 and perhaps IL-33 [64, 65].

Human mast cell chymase was demonstrated to convert pro-IL-18 into biologically active IL-18 fragments [66]. Cutaneous mastocytosis is a common feature of atopic dermatitis in humans and also in murine models, such as skin-specific caspase-1 transgenic (tg) mice and IL-33 tg mice [67, 68]. In these mouse models, chronic dermatitis spontaneously develops with severe mastocytosis in the skin lesions. As IL-18 and IL-33 are potent activators of mast cells [69, 70], it is plausible that mast cells in the lesion release chymase. Chymase might, in turn, cleave pro-IL-18, which is liberated from the damaged keratinocytes, into active fragments. This might serve as a positive feedback circuit for exacerbation of chronic dermatitis in either mouse model.

Granzyme B is a cysteine protease, produced by natural killer cells and cytotoxic T lymphocytes, that is involved in apoptosis of target cells [71]. Recently, granzyme B was shown to exert processing activity on pro-IL-18 [72], although the biological settings involving granzyme B-mediated IL-18 processing are unclear.

As described below, many IL-1 family cytokines are produced as full-length proteins in nonhematopoietic cells, including epithelial cells, fibroblasts, and endothelial cells (Table 1). Membrane-bound and secreted astacin metalloproteinases, meprins, were verified to have the potential to cleave pro-IL-1β and pro-IL-18 into bioactive fragments [73, 74]. Meprin α is reported to be expressed in the stratum basale of human skin, whereas meprin β is observed in the cells of the stratum granulosum. Intriguingly, in the lesions of patients with psoriasis vulgaris, meprin α expression is predominant in the uppermost layers rather than the basal layer [75, 76]. This indicates that meprins may be involved in processing of IL-36 subfamily cytokines, which are preferentially expressed in the skin (as described above). Meprin β, but not meprin α, has been shown to be essential for IL-18 processing in a murine model of colitis induced by dextran sulfate sodium (DSS). After challenge with DSS, meprin β-deficient mice, but not meprin α-deficient mice, display a significant reduction in the elevation of serum levels of IL-18 in comparison with WT mice [74]. Thus, in nonhematopoietic cells, meprins are IL-1β- and IL-18-converting enzymes.

Previously, inflammasome-independent enzymes were believed to be involved in the processing of IL-1β in autoimmune inflammatory disease of Pstpip2tm−/− mice [77–81]. Pstpip2tm−/− mice express a Leu98Pro missense mutation in the Pombe Cdc15 homology family protein proline serine-threonine phosphatase interacting protein 2 (PSTPIP2) and develop osteomyelitis when they are fed a normal, low-fat diet. Pstpip2tm−/−Il1β−/− and Pstpip2tm−/−Il1r1−/− mice are free of osteomyelitis, whereas Pstpip2tm−/−Nlrp3−/− and
Inflammation induced by extrinsic microbial infection, this is triggers or exacerbates inflammatory diseases. In contrast to derived substances, such as PAMPs translocated from the response can be evoked upon exposure to stimuli from host-derived substances, such as PAMPs translocated from the gut microbiome or self-derived alarmins and DAMPs. This triggers or exacerbates inflammatory diseases. In contrast to inflammation induced by extrinsic microbial infection, this is known as sterile inflammation. Sterile inflammation underlies many types of local inflammatory diseases [84]. IL-1α has been demonstrated to play a major role in the development of sterile inflammatory diseases including atherosclerosis and myocardial infarction [85, 86]. Indeed, intraperitoneal administration of dead endothelial cell-derived particles can induce peritonitis in mice, dependent on IL-1α but not IL-1β [87]. Furthermore, it has been demonstrated that the mode of cell death largely determines whether cells release IL-1α, IL-1β, or neither [88]. Apoptosis and pyroptosis are two types of regulated cell death; necroptosis is a third. In contrast to apoptosis, pyroptosis and necroptosis are characterized by destruction of the cellular membrane. Apoptotic cells do not release their cellular contents, whereas both necrotic and pyroptotic cells liberate their cellular contents, including IL-1α [48]. Pyroptosis, a type of inflammatory cell death induced by inflammasome activation as described above, is accompanied by IL-1β release. Necroptosis is mediated by receptor interacting protein kinase-3 (RIP3) and by its substrate, mixed lineage kinase like (MLKL), which is located in the cytosol [49, 89]. RIP3-phosphorylated MLKL is oligomerized and translocated to the plasma membrane, where it destroys the cell membrane by disruption of ion channels and/or induction of pore formation [90–93]. Necroptosis develops when cells are stimulated via cell death receptors, such as TNFRI, Fas, and receptors of TNF-related apoptosis-inducing ligand (TRAIL), under limited, apoptosis-inhibiting conditions. Other stimuli, such as TLR ligands, viral infection, and type 1 IFN, can induce necroptosis as well [49]. Unfortunately, no method has been established for selectively distinguishing necrotic cell death from other types of cell death. Necroptosis can liberate IL-1α. In addition to IL-1α, IL-1β is responsible for sterile inflammation, because DAMPs in the liberated cellular contents can activate innate immune responses including inflammasome-mediated IL-1β release. Therefore, it is plausible that both IL-1α and IL-1β are involved in sterile inflammation [84].
Recent progress in antibody technology and tools for identification of disease-responsible genes has enabled cures for many patients with recurrent or chronic inflammatory diseases. In particular, many inflammatory diseases can be efficiently treated by IL-1 blockade. For example, patients with hereditary systemic autoimmune inflammatory disease due to impaired regulation of inflammasome activation or impaired regulation of IL-1 signaling can be treated with an IL-1Ra named Anakinra and/or a soluble IL-1R named Rilonacept [13, 94–97]. Type 2 diabetes, to which the aberrantly activated inflammasome has been shown to be relevant [98–100], can also be treated with IL-1Ra [101].

5.2. IL-33. Analogous to IL-1α, IL-33 is liberated following cell death accompanied by cell membrane rupture (i.e., necroptosis but not apoptosis) [19].

Endogenous IL-33 is important for the type 2 immune response against helminth infection. Several cell types involved in innate immunity, such as group 2 innate lymphoid cells (ILC2), basophils, eosinophils, and mast cells, express IL-33R and play a role in triggering and/or enhancement of type 2 immunity. In particular, in response to IL-33, ILC2 promptly produces large amounts of IL-5 and IL-13, which eventually leads to eosinophilia and mucin accumulation around the helminth. IL-33-mediated ILC2 activation is important for the rapid development of Löffler syndrome, which is characterized by pulmonary eosinophilia after cutaneous infection of mice with intestinal nematode larva [102]. This type of ILC2-mediated host response is critical for the expulsion of intestinal nematodes via induction of parasite-specific type 2 immunity [103]. Thus, IL-33 activation of ILC2 is required for host defense against helminths via activation of both innate and acquired immune responses [104, 105].

Cerebral malaria, induced by infection with the protozoan Plasmodium spp., is a lethal disease in children. Th1 immunity against the protozoan is important for host defense but simultaneously activates collateral severe inflammation in the brain. Very recently, extrinsic IL-33 was demonstrated to protect against lethal cerebral malaria by activating ILC2, inducing regulatory T cells, and causing cellular conversion into M2 Mø that produce anti-inflammatory and regulatory cytokines [106].

IL-33 is pivotal for allergic diseases as well. ILC2 plays a role in the development of allergic airway inflammation [107–111]. For example, peripheral blood mononuclear cells (PBMCs), including ILC2, prepared from patients with allergic asthma produce larger quantities of IL-13 and IL-5 in response to IL-33 than those from control subjects [112]. In addition, the IL-33/IL-33R axis in mast cells and basophils participates in allergic respiratory diseases [113]. After intranasal infection of mice with a mouse parainfluenza virus, Sendai virus, chronic obstructive pulmonary disease (COPD) develops. The virus-infected WT mice show elevated airway resistance, whereas IL-33- and ST2-deficient mice do not [114]. The IL-33-IL-33R axis is also important for airway inflammation and for induction of IL-33 downstream cytokines and mucin. Notably, lung samples from patients with COPD exhibit higher levels of IL-33 in their lung epithelial cells than those from non-COPD patients [114]. IL-33 is essential for the development of allergic rhinitis induced by intranasal treatment with ragweed in mice [115]. This is also true for food allergies induced by topical application of peanut extracts [116]. Furthermore, Il33 tg mice, which specifically overexpress IL-33 in their keratinocytes, spontaneously develop atopic dermatitis-like chronic cutaneous alterations [68].

Accumulating lines of evidence strongly suggest that IL-33 is involved in fibrotic diseases, an important cause of morbidity and mortality in humans. It is well established that type 2 immune responses involving cell conversion into M2 Mø are important for wound healing and fibrosis [117–120]. Because IL-33 is associated with type 2 immunity, as described above, it is plausible that IL-33 is causative of fibrotic diseases [121]. Serum levels of IL-33 are elevated in patients with systemic sclerosis, a connective tissue disease characterized by fibrosis of the skin and other organs, such as the lungs [122]. There is a positive relationship between serum IL-33 levels and disease severity [123]. In addition, daily subcutaneous injection of IL-33 induces cutaneous fibrosis in WT mice and mast cell-deficient mice (cKitΔ−/−) but not in St2Δ−/−, Il33Δ−/−, Rag2Δ−/−, or eosinophil-deficient mice (ΔdblGATA mice), indicating the importance of aberrant accumulation of IL-33, its downstream cytokine IL-13, acquired immunity, and eosinophils [124]. Large numbers of cells expressing abundant IL-33 are observed in the lungs of patients with idiopathic pulmonary fibrosis, as well as systemic sclerosis [125]. Furthermore, gene-delivery of Il33 exacerbates bleomycin-induced pulmonary fibrosis [125, 126]. The roles of IL-33 in liver cirrhosis will be described in a subsequent section.

5.3. IL-18. IL-18 is a pleiotropic cytokine, similar to other IL-1 agonists, and its major biological functions have been described in several reviews [69, 127–130]. For example, IL-18 contributes to both type 1- and type 2-mediated host defense and inflammatory diseases. In collaboration with IL-12, IL-18 activates NK cells to produce a large quantity of interferon-γ (IFN-γ). Convincingly, Il18Δ−/− mice are highly susceptible to infection with the intracellular bacterium Listeria monocytogenes, particularly in the early infectious phase [131]. IL-18 is also involved in the expulsion of the intracellular fungus Cryptococcus neoformans. In addition, together with IL-2, IL-18 activates NKT cells and T helper (Th) cells to produce the Th2-related cytokines, IL-4 and IL-13 [132]. IL-18 is known to be beneficial for the expulsion of the intestinal nematode, Strongyloides venezuelensis [133]. Unexpectedly, IL-18 activates Th1 cells to produce IL-13 and chemokines as well as Th1-related cytokines [134]. Based on this biological function, IL-18 can trigger the development of intrinsic atopic dermatitis and bronchial asthma, in which both IFN-γ and IL-13 play a critical role [67, 135, 136].

IL-18 has also been reported to be involved in metabolic syndrome [137]. In contrast to IL-1 [101], however, IL-18 protects against metabolic syndrome, although patients with the metabolic syndrome show increased serum levels of IL-18 [138, 139].
5.4. IL-37. In 2001, database analyses identified a new, IL-18Rα-binding human protein named IL-37 [140]. To date, its mouse orthologue has not been identified. Various cell types have been reported to produce IL-37. IL-37 is a potent inhibitor of both innate and acquired immune responses. IL-37tg mice are resistant to LPS-induced shock and DSS colitis compared to WT mice [141, 142]. IL-37 is associated with Behçet’s disease, an intractable, chronic inflammatory disease [143]. IL-37 also dampens type 2 immune responses. Indeed, intranasal administration of human IL-37 ameliorates ovalbumin-induced type 2 allergic airway inflammation [144]. Upon IL-37 engagement, IL-18R recruits SIGIRR/TIR8, which negatively regulates many signaling pathways, including phosphatase and tensin homolog deleted from chromosome 10 (PTEN) and signal transducers and activators of transcription-3 (STAT-3), to inhibit transforming growth factor β activated kinase-1 (TAK-1) and the transcription factors NF-κB and MAPKs and to interact with Smad3, an anti-inflammatory signaling molecule [141, 145]. The full network that is activated by IL-37-mediated signaling remains to be elucidated.

5.5. IL-36. The IL-36 subfamily includes IL-36α, IL-36β, IL-36γ, IL-36Ra, and IL-38. All were discovered by database searches on the basis of their homology with IL-1α and IL-1β [8, 146]. IL-36 cytokines are expressed in the skin under normal conditions [147]. Skin-specific IL36α tg mice develop psoriasis-like skin alterations; they spontaneously suffer from flaky skin within 1 week of birth, but by week 3 their skin phenotypes have disappeared [148]. Thereafter, they exhibit recurrence of skin lesions. Treatment with anti-IL-23, anti-TNF, or anti-IL-36R antibodies rescues IL36α tg mice from the skin alterations [149]. Furthermore, following topical application of the ligand of TLR7/TLR8, imiquimod, IL36ra−/− mice develop more severe psoriasis-like skin alterations than WT mice. In contrast, IL23−/− and IL17a−/− mice are resistant to imiquimod-induced psoriasis [150]. Several reports identified a homozygous missense mutation in IL36RN that encodes IL-36Ra in patients with familial generalized pustular psoriasis and found that the mutations in IL36RN cause poor affinity or labile binding of IL-36Ra to IL-36R [151–153]. Thus, impaired IL-36Ra function might be responsible for the development of generalized pustular psoriasis. In addition, IL-36 agonists might be involved in sporadic psoriasis [154]. IL-38 is a recently identified IL-1 family antagonist that is reported to function similarly to IL-36Ra [155]. However, the biological roles of IL-38 remain to be elucidated.

6. The Roles of IL-1 Family Members in Liver Diseases

As mentioned, IL-1 family agonists and antagonists are involved in health and disease, and it is plausible that these molecules are involved in liver diseases. This section highlights recent advancements in the understanding of the molecular and cellular mechanisms of liver diseases associated with IL-1 family cytokines, particularly focusing on IL-1, IL-33, and IL-18.

6.1. IL-1 and IL-18 in Viral Hepatitis (Figure 4). Because the viruses that cause liver diseases in humans are species-specific, it is difficult to demonstrate the mechanism of viral hepatitis in animal models other than primates, limiting advancement in the study of viral hepatitis. Study of immunodeficient mice with transplanted human liver cells and receiving human autologous hematopoietic stem cells may shed light on this issue. Mice with human liver and immune cells developed by induced pluripotent stem cells (iPSCs) show promise of becoming a useful tool in the near future.

6.1.1. Hepatitis B Virus. It is well established that types I, II, and III IFNs directly inhibit the replication of hepatitis B virus (HBV) [156]. Recently, Watashi et al. demonstrated that IL-1 can protect against HBV infection [157]. The authors incubated hepatocytes with IL-1β, and after vigorous washing of the cells they added HBV to the cell culture. After 4 days of incubation they measured HBV replication. In this setting, IL-1β protected against HBV infection, whereas IFN-α, an HBV replication inhibitor, did not, suggesting that IL-1β inhibits the early phase of HBV infection, including attachment, entry, and nuclear import. This restriction of HBV infection is mediated by activation-induced cytidine deaminase (AID) induced by IL-1α/IFN-κB signaling. Indeed, introduction of AID suppresses the permission of HBV. Thus, IL-1β can restrict HBV infection via induction of AID, although the molecular mechanism underlying the AID-mediated restriction is unknown. Intriguingly, HBeAg, a soluble protein produced by HBV, can inhibit production of IFN-γ from IL-12/IL-18-activated NK cells via downregulation of IL-18/IFN-κB signaling [158]. Indeed, serum from HBeAg-positive patients induces lower IFN-γ production by IL-12/IL-18-stimulated NK cells than that from HBeAg-negative patients [158]. The liver contains abundant NK cells, which were initially named “pit cells” on the basis of their unique localization in the hepatic sinusoid [159], as well as Kupffer cells, which have the potential to produce both IL-18 and IL-12 in the same anatomical compartment. Thus, after microbial infection, robust IFN-γ is promptly produced by the intimate interaction between NK cells and Kupffer cells. HBV may evade this IFN-γ production by releasing HBeAg and can easily infect hepatocytes.

6.1.2. Hepatitis C Virus. Type I and type III IFNs are important for eradication of HCV [160]. It is well documented that serum levels of IL-18 are elevated in chronic HCV patients. IL-18 levels reflect the severity and activity of HCV infection [161]. THP-1 cells or monocyte-derived Mø produce IL-1β and IL-18 after infection with HCV [162]. This HCV-induced IL-1β/IL-18 production requires activation of the TLR7/MyD88 pathway, but not TLR3/TRIF, and of NLRP3 inflammasomes. In contrast, IFN-α production requires mitochondrial antiviral-signaling protein (MAVS), which is an essential signal adaptor for the signaling of RIG-1-like receptors (RLRs), which are sensors of viral products. Thus, upon HCV infection, distinct modes of RRP signaling participate in production of IL-1β/IL-18 and IFN-α [163, 164].
6.2. The Importance of Necroptosis in IL-1α-Mediated Liver Diseases (Figure 4). As described above, necroptosis is a form of regulated cell death that involves cellular membrane rupture. Necroptosis-driven liberation of the cell contents, including IL-1α, is important for the activation of sterile inflammation, which is a powerful mechanism for amplifying inflammation (described below). Hepatocyte necroptosis is involved in various liver diseases [165]. Acetaminophen (APAP) overdose is a predominant cause of acute, hepatotoxic liver failure in the USA and UK. An APAP-derived metabolite has been shown to have direct hepatocytotoxic action. Recent studies suggested that necroptotic hepatocyte death is a direct pharmaceutical effect of the APAP metabolite [166]. The liver of APAP-treated mice showed induction of RIP3, a key molecule that induces necroptosis, and RIP3 morpholin treatment protected against APAP-induced liver injury. In addition, Rip3^−/−^ hepatocytes are somewhat resistant to APAP. Very recently, Li et al. demonstrated that APAP-induced liver injury is induced by necroptosis of hepatocytes [167]. They verified that the B-Raf*V600E* inhibitor dabrafenib, which is an anticancer drug, is a potent RIP3 inhibitor as well. Dabrafenib can inhibit necroptosis of human hepatocytes incubated with APAP. Importantly, inhibition of cell death by the RIP1 inhibitor necrostatin-1 had been regarded as a hallmark of necroptosis, but this inference is made dubious by the evidence of RIP1-independent necroptosis [49]. Thus, the necrostatin-1 test is not always useful for diagnosis of necroptosis. Similarly, necrostatin-1 treatment does not improve APAP-induced hepatocyte cell death [167]. Notably, positive staining for phosphorylated MLKL, a hallmark of necroptosis, has been observed in the hepatocytes of patients with APAP-induced liver failure [92]. Necroptosis has also been demonstrated to be relevant to ethanol-induced liver injury in mice [168]. This is also the case in liver biopsy of patients with alcoholic liver disease (ALD). Thus, some drug-induced liver injuries appear to develop in a manner dependent on RIP3-mediated necroptosis.

Ischemia-reperfusion injury of the kidney or retina was also demonstrated to be caused by necroptosis [169, 170]. Similarly, ischemia-reperfusion-induced liver injury might also involve the necroptotic death of hepatocytes. A precise analysis of whether and how necroptosis is involved in ischemia-reperfusion-induced liver injury would be useful.

RIP3 is overexpressed in the livers of patients with NASH [171]. In this paper, the authors showed that WT mice were susceptible to diet-induced NASH, whereas Rip3^−/−^ mice, which lack the capacity for necroptosis, were resistant. Therefore, necroptosis might underlie hepatocytic cell death during NASH. However, the endogenous factor(s) that are responsible for the initiation of RIP3-mediated necroptosis remain to be elucidated.

6.3. Sterile Inflammation Mediated by IL-1α and IL-1β (Figure 4). Necroptotic hepatocytes in NASH, drug-induced liver injury, and possibly ischemia-reperfusion-induced liver injury can trigger sterile inflammation by activation of...
the NLRP3 inflammasome with liberated DAMPs and/or by IL-1α. It has been clearly demonstrated that saturated, but not unsaturated, free fatty acid (FFA), which is a host-derived metabolite, is capable of activating the NLRP3 inflammasome to produce IL-1β and that this IL-1β might lead to progression to NASH in mice with simple hepatic steatosis [172, 173]. The following scenario has been proposed. Saturated FFA can inhibit autophagy, especially mitophagy, in cells. Under normal conditions, impaired mitochondria are rapidly eliminated via mitophagy. However, saturated FFA-induced impairment of mitophagy might allow long-term retention of impaired mitochondria. Subsequently, aberrant production of reactive oxygen species (ROS) by the impaired mitochondria might continuously and robustly activate ROS-sensitive inflammasomes [172]. Miura et al. reported that the induction and exacerbation of NASH were explained by IL-1β, which is produced by the activation of TLR9/MyD88 signaling, and the NLRP3 inflammasome by DAMPs, possibly derived from necroptotic hepatocytes [174]. In fact, Tlr9−/− mice are resistant to diet-induced NASH and show accompanying reduced induction of serum elevation of IL-1β. Consistently, Myd88−/− and Il1r1−/− mice show resistance to NASH similar to Tlr9−/− mice. The authors reported that Kupffer cells were a major cellular source of IL-1β, which accelerated cytoidal lipid deposits in hepatocytes, induced cell death, and simultaneously activated hepatic stellate cells to produce profibrotic proteins. Tlr2−/− mice evade NASH via impaired induction of IL-1α and IL-1β, even when fed a NASH-prone diet [175]. The importance of hematopoietic cells, including Kupffer cells, for the development of NASH via activation of TLR2 has been demonstrated in chimeric mice. Indeed, Tlr2−/− Kupffer cells cannot produce IL-1α or IL-1β after stimulation with saturated free fatty acid palmitate together with TLR2 agonists. Sterile inflammation is also activated by hepatocyte-derived IL-1β. Hepatocytes prepared from mice suffering from NASH express enhanced levels of NLRP3 inflammasome components and have the capacity to release IL-1β in response to palmitate, a saturated fatty acid, in combination with LPS [176]. Consistently, treatment with pan-caspase inhibitors such as Emricasan and VX-166 can suppress liver injury, inflammation, and fibrosis in mice fed a NASH-prone, high-fat diet [177]. In contrast to IL-1, IL-18 is reported to be beneficial for preventing NASH. IL-18 secreted following activation of the NLRP3 inflammasome negatively regulates the development of murine NASH through maintenance of a healthy gut microbiota [178, 179]. This may imply that the harmful effects of IL-1β might overcome the beneficial action of endogenous IL-18.

Sterile inflammation is involved in the exacerbation of APAP-induced acute liver failure [180]. Imaeda et al. showed that treatment with a TLR9 antagonist and deletion of Tlr9 decreased the severity of APAP-induced liver failure with impaired induction of proIL-1β. NLRP3 inflammasome-deficient mice, such as Caspase1−/−, Asc−/−, and Nlrp3−/− mice, showed comparably reduced induction of liver failure to Tlr9−/− mice. This suggests that DAMPs, including a TLR9 agonist, which are liberated from APAP-induced necrotic hepatocytes, might activate the TLR9 pathway and the NLRP3 inflammasome.

The TLR9-mediated signal pathway has also been demonstrated to participate in the activation of sterile liver inflammation induced by ischemia and reperfusion [181]. A scenario similar to that of NASH and APAP-induced acute liver failure underlies the progression of this disease as well. An excellent review has been published that is helpful in understanding the other mechanisms underlying sterile inflammation in hepatic ischemia-reperfusion-induced liver injuries [182].

In the above-mentioned liver diseases, sterile inflammation may accelerate disease progress, such as lethal liver failure and fibrosis. However, the pathway that links TLR/MyD88-mediated pro-IL-1β production to activation of the NLRP3 inflammasome remains to be elucidated.

6.4. IL-33 in Liver Fibrosis (Figure 5). Until recently, liver cirrhosis was regarded as the irreversible end stage of chronic liver disease. However, recent studies have revealed that liver fibrosis is reversible. Many cell types, such as Mø, pro-fibrotic myofibroblasts, which are mainly transdifferentiated from stellate cells, and innate and acquired immune lymphocytes, participate in the development of liver fibrosis. The mechanisms underlying the initiation of liver fibrosis have been gradually unraveled by intensive efforts using animal models and clinical data. For example, pro-fibrotic and pro-resolving Mø have been shown to contribute to the progression and regression of liver fibrosis, respectively [183, 184]. A comprehensive discussion of the cellular and molecular mechanisms of liver fibrosis discovered to date is out of the scope of this review. For further information, the reader may consult recent expert reviews [185–188]. Herein, we will focus on the roles of IL-33 in liver fibrosis.

The importance of IL-33 for liver fibrosis was demonstrated by analyses of several mouse models of liver fibrosis. Multiple injections of carbon tetrahydrochloride (CCl4) or thioacetamide, infection with the helminth Schistosoma mansoni, or bile duct ligation induces liver fibrosis in WT mice, accompanied by elevation of serum IL-33 levels [189, 190].
IL-33-expressing cells are accumulated in the fibrotic liver, particularly in αSMA+ cells [189, 190]. Il33−/− mice are resistant to induction of liver fibrosis by these treatments. Intriguingly, multiple introduction of Il33 in the liver of mice induces liver fibrosis. St2+/+, Il33+/−, and Il4ra−/− mice are resistant to this treatment, strongly suggesting that the IL-33–IL-13 axis is important for the development of IL-33-induced liver fibrosis. Rag1−/− mice lack both T- and B-lymphocytes but normally possess group 2 ILC (ILC2), which are capable of responding to IL-33 by prompt and robust production of type 2 cytokines including IL-13 [191–193]. Intriguingly, in vivo depletion of ILC2 prevents Rag1−/− mice from developing IL-33-induced liver fibrosis. Thus, the IL-33–ICL2–IL-13 axis is critical for development of some types of liver fibrosis. Consistent with data from mice, serum levels of IL-33 are elevated in patients with liver cirrhosis [189]. In addition, Il33 and St2 expression levels in cirrhotic livers positively correlate with disease severity.

The IL-33–ILC2–IL-13 axis has also been demonstrated to be involved in biliary repair and possibly in carcinogenesis in the biliary tract. Biliary atresia is a bile duct disease that is common in childhood. A subset of patients with biliary atresia display an increase in pro-Th2 cytokines. Recently, it was demonstrated that the IL-33–ILC2–IL-13 axis plays a pivotal role in the development of biliary atresia-associated biliary repair and carcinogenesis [194, 195]. Serum IL-33 levels are elevated in patients with biliary atresia. Expression levels of Il33 mRNA are correlated with numbers of replicating cholangiocytes in an experimentally induced mouse model of biliary atresia. Biliary atresia is induced by infection of neonate mice with rhesus rotavirus type A (RRP). Treatment with anti-ST2 antibodies inhibits cholangiocyte replication in RRP-challenged mice. Conversely, extrinsic IL-33 treatment induces profound replication of extrahepatic cholangiocytes. Lcl2-deficient Rag2+/−γc−/− mice, as well as Il13−/− mice, fail to show cholangiocyte growth upon IL-33 treatment. Thus, the IL-33–ILC2–IL-13 axis is important for bile duct repair. Similarly, it was reported that IL-33 facilitated oncogene-induced cholangiocarcinoma in mice [196].

6.5. IL-33 in Obesity, a Precondition for NASH (Figure 6). IL-33/ST2 signaling protects against obesity-associated inflammation in visceral adipose tissue (VAT) and maintains insulin sensitivity. It is well established that chronic, low-grade inflammation involving Mø in VAT links obesity to metabolic diseases [197, 198]. In parallel, regulatory T cells (Treg) are functionally and numerically reduced in the VAT of obese mice, which might partly explain the dysregulated inflammation observed in the VAT of obese mice [198, 199]. Multiple injections of IL-33 improved insulin sensitivity and glucose tolerance in ob/ob mice, concomitant with cellular conversion into anti-inflammatory M2 Mø in their VAT [200]. Consistent with this, St2+/+ mice were highly susceptible to HFD-induced impairment of glucose tolerance. IL-33 treatment could reverse the deficit of ST2+ Treg in diet-induced obese mice [201]. Furthermore, accumulation of Treg in the VAT of lean, aged mice was reported to be dependent on IL-33 in VAT. Indeed, the proportion of Treg in CD4+ T cells in the VAT of St2+/+ mice is reduced compared to that of WT mice. Conversely, IL-33 treatment increases the proportion of Treg [202, 203]. In addition, ILC2 is required for the accumulation of eosinophils and cell conversion to M2 Mø in the VAT via production of IL-5 and IL-13 [204].
White adipose tissue (WAT) stores energy. Unlike WAT, brown adipose tissue (BAT) contributes to energy consumption via thermogenesis and is regarded as a possible target organ for treatment of obesity. Although the VAT is lost by adulthood in humans, adult humans harbor beige adipocytes that express a thermogenic protein, uncoupling protein 1 (UCP1), in subcutaneous WAT (SAT) in cold conditions. Thus, beige fat shows promise as a therapeutic target for the treatment of obesity. It has been demonstrated that both IL-4 production by eosinophils and the IL-4 responsiveness of M2 macrophages are equally required for the development of thermogenic beige fat that expresses UCP1 [205]. Brestoff et al. and Lee et al. independently demonstrated that, in this setting, IL-33 activation of ILC2 is important for beiging [206, 207]. In obese humans, the SAT harbors lower numbers of ILC2 than in nonobese humans. This is also true for diet-induced obese WT mice. IL33−/− mice harbor small numbers of ILC2 in the SAT and show higher gain of body and fat mass than WT mice, even when fed a normal, low-fat diet. The SAT of IL33−/− mice is characterized by the presence of few beige adipocytes and by much lower expression of Ucp1, whereas in WT mice the SAT as well as the VAT harbors substantial numbers of beige adipocytes. IL-33 administration induces an increase in ICL2 in the SAT and enhances calorie expenditure in WT mice. Transfer of ILC2 prepared from IL-33-treated WT mouse SAT upregulates Ucp1 expression in the SAT and increases energy expenditure in WT mice. Transfer of ILC2 induces SAT Ucp1 expression in ILC2-null Rag2−/−γc−/− mice as well. Levels of proprotein convertase subtilisin/kexin type 1 (Psec1), an endopeptidase involved in processing prohormones into active form, were shown to increase in ILC2 [206]. Following administration of methionine-enkephalin peptide, which is a substrate of PCSK1, WT mice showed increased numbers of UCP1 beige adipocytes and increased energy consumption. This may imply that IL-33 induces beiging in the WAT, at least partly via production of methionine-enkephalin peptide. Taken together, these results show that endogenous IL-33 sustains beige adipocytes in the SAT by activating ILC2, presumably in collaboration with M2 Mø and eosinophils, which eventually contributes to metabolic homeostasis by tuning calorie expenditure. Endogenous opioid-like peptides, including the methionine-enkephalin produced by IL-33-activated ILC2, show promise as a potent therapeutic agent for obesity and obesity-associated diseases.

7. Closing Remarks

Recent studies have revealed the importance of ILC2 in health and disease. ILC2 plays a critical role in the development of liver fibrosis and in protection against obesity. However, these conclusions were drawn from studies using mouse models, and although the definition of mouse ICL2 is well established, definitions of human ILC2 differ among research groups [208, 209]. A uniform definition of ICL2 will be required to make progress in the translation of the findings on murine ICL2 to human diseases.

NASH is characterized by liver fibrosis. Overexpression of IL-33 can induce liver fibrosis in mice. However, it remains to be elucidated whether endogenous IL-33 is involved in diet-induced NASH fibrosis. Many investigators have reported the elevation of IL-33 or IL-33 mRNA levels in the liver or in circulation. However, it remains unclear whether the IL-33 elevation is a result of or relevant to liver fibrosis. To address this, we must examine whether IL33−/− and St2−/− mice are resistant to liver fibrosis. In addition, the cellular source of IL-33 in these diseases remains unknown. Liver parenchymal cells have been shown to be a major cellular source of IL-33 in the liver under normal conditions. During the progression of NASH, α-SMA-expressing myofibroblasts become the predominant IL-33-producing cell type. However, this does not indicate whether myofibroblast-derived IL-33 initiates and/or exacerbates liver fibrosis, because we do not know whether or how the myofibroblasts undergo the necroptotic or pyroptotic cell death that allows liberation of intracellular IL-33. It is well documented that hepatocytes become necroptotic under NASH conditions (Figure 4), suggesting that hepatocytes might be a major continuous cellular source of IL-33 during NASH.

Obesity is an important problem in both developed and developing countries. Obesity plays a central role in the development of various life-threatening diseases, including cardiovascular diseases and cancers. However, the causes of the rapid, global increase in obesity remain to be elucidated. Recent studies clearly demonstrate that artificial sweeteners and dietary emulsifiers, which are a common part of the daily diet, are responsible for the development of metabolic syndrome in mice [210, 211]. Eating a diet without these agents might be important for health. In addition, several active compounds in a “healthy diet” have been identified. The biological compounds thymoquinone, curcumine, and resveratrol can be purified from Nigella sativa (black seed), Zingiberaceae spp. (e.g., ginger and turmeric), and grape skins, respectively [212–214]. These compounds are beneficial for human health. Many traditional foods have been shown to promote health. The identification of pro-health compounds will contribute to human health and longevity.

Abbreviations

- AID: Activation-induced cytidine deaminase
- AIM2: Absent in melanoma 2
- ALD: Alcoholic liver disease
- APAP: Acetaminophen
- ASC: Apoptosis-associated speck-like protein containing a carboxy-terminal CARD
- BAT: Brown adipose tissue
- B6: C57BL/6
- CARD: Caspase recruitment domain
- CCL4: Carbon tetrachloride
- COPD: Chronic obstructive pulmonary disease
- DAMPs: Damage-associated molecular patterns
- DSS: Dextran sulfate sodium
- FFA: Free fatty acid
- HBV: Hepatitis B virus
- HFD: High-fat diet
- ICE: IL-1β-converting enzyme
- IFN: Interferon
- IGF1: Interferon inducing factor
Mediators of Inflammation

IL: Interleukin
IL-18BP: IL-18-binding protein
IL-1Ra: IL-1R antagonist
ILC: Innate lymphoid cells
ILC2: Group 2 ILC
JNK: c-Jun N-terminal kinase
MAPK: Mitogen-activated protein kinase
LPS: Lipopolysaccharide
LRR: Leucine-rich repeat
MAVS: Mitochondrial antiviral-signaling protein
MLKL: Mixed lineage kinase like
Mo: Macrophages
NF-κB: Nuclear factor-κB
NLR: Nod-like receptor
NLRP: NACHT, LRR, and PYD-containing protein
Pro: Precursor
PAMPs: Pathogen-associated molecular patterns
PYD: Pyrin domain
PBMC: Peripheral blood mononuclear cells
PCSK1: Proprotein convertase subtilisin/kexin type 1
Penk: Proenkephalin A
PR3: Proteinase 3
PRR: Pattern recognition receptor
PSTPIP2: Prolineserine-threonine phosphatase interacting protein 2
R: Receptor
RIP: Receptor interacting protein kinase
RLR: RIG-I-like receptor
RPP: Rhesus rotavirus type A
SAT: Subcutaneous WAT
SIGIRR: Single immunoglobulin IL-1-related receptor
Th: T helper
TIR: TLR/IL-1R
TLR: Toll-like receptor
TRIF: TIR-domain-containing adapter-inducing interferon-β
TRAIL: TNF-related apoptosis-inducing ligand
Treg: Regulatory T cells
UCP1: Uncoupling protein 1
VAT: Visceral adipose tissue
WAT: White adipose tissue
WT: Wild-type.

Conflict of Interests

The authors declare no conflict of interests.

Acknowledgment

This study was partly supported by the MEXT-Supported Program for the Strategic Research Foundation at Private Universities, 2012–2015.

References

[1] C. A. Dinarello, “Overview of the interleukin-1 family of ligands and receptors,” Seminars in Immunology, vol. 25, no. 6, pp. 389–393, 2013.
[2] S. Haskill, G. Martin, L. Van Le et al., “cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 9, pp. 3681–3685, 1991.
[3] H. Okamura, H. Tsuetsu, T. Komatsu et al., “Cloning of a new cytokine that induces IFN-γ production by T cells,” Nature, vol. 378, no. 6552, pp. 88–91, 1995.
[4] J. F. Bazan, J. C. Timans, and R. A. Kastelein, “A newly defined interleukin-1?” Nature, vol. 379, article 591, 1996.
[5] Y. Gu, K. Kuida, H. Tsutsumi et al., “Activation of interferon-γ inducing factor mediated by interleukin-1R converting enzyme,” Science, vol. 275, no. 5297, pp. 206–209, 1997.
[6] K. Hoshino, H. Tsuetsu, T. Kawai et al., “Cutting edge: generation of IL-18 receptor-deficient mice: evidence for IL-1 receptor-related protein as an essential IL-18 binding receptor,” The Journal of Immunology, vol. 162, no. 9, pp. 5041–5044, 1999.
[7] J. Schmitz, A. Owyang, E. Oldham et al., “IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines,” Immunity, vol. 23, no. 5, pp. 479–490, 2005.
[8] C. A. Dinarello, W. Arend, J. Sims et al., “IL-1 family nomenclature,” Nature Immunology, vol. 11, no. 11, article 973, 2010.
[9] C. Garlanda, C. A. Dinarello, and A. Mantovani, “The interleukin-1 family: back to the future,” Immunity, vol. 39, no. 6, pp. 1003–1018, 2013.
[10] F. L. van de Veerdonk and M. G. Netea, “New insights in the immunobiology of IL-1 family members,” Frontiers in Immunology, vol. 4, article 167, 2013.
[11] L. R. Lopetuso, S. Chowdhry, and T. T. Pizarro, “Opposing functions of classic and novel IL-1 family members in gut health and disease,” Frontiers in Immunology, vol. 4, article 181, 2013.
[12] C. Garlanda, H.-J. Anders, and A. Mantovani, “TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization,” Trends in Immunology, vol. 30, no. 9, pp. 439–446, 2009.
[13] C. A. Dinarello, A. Simon, and J. W. M. van der Meer, “Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases,” Nature Reviews Drug Discovery, vol. 11, no. 8, pp. 633–652, 2012.
[14] C. Gabay and J. E. Towne, “Regulation and function of interleukin-18 cytokines in homeostasis and pathological conditions,” Journal of Leukocyte Biology, vol. 97, no. 4, pp. 645–652, 2015.
[15] D. Novick, S.-H. Kim, G. Fantuzzi, L. L. Reznikov, C. A. Dinarello, and M. Rubinstein, “Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response,” Immunity, vol. 10, no. 1, pp. 127–136, 1999.
[16] O. Adachi, T. Kawai, K. Takeda et al., “Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function,” Immunity, vol. 9, no. 1, pp. 143–150, 1998.
[17] Y. Kondo, T. Yoshimoto, K. Yasuda et al., “Administration of IL-33 induces airway hyperresponsiveness and goblet cell hyperplasia in the lungs in the absence of adaptive immune system,” International Immunology, vol. 20, no. 6, pp. 791–800, 2008.
[18] A. Werman, R. Werman-Venkert, R. White et al., “The precursor form of IL-1α is an intracrine proinflammatory activator of transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 8, pp. 2434–2439, 2004.
underlies endotoxin-induced liver injury in mice," *Gastroenterology Research and Practice*, vol. 2010, Article ID 641865, II pages, 2010.

[37] N. Kayagaki, S. Warming, M. Lamkanfi et al., "Non-canonical inflammasome activation targets caspase-11," *Nature*, vol. 479, no. 7371, pp. 117–121, 2011.

[38] N. Kayagaki, M. T. Wong, I. B. Stowe et al., "Noncanonical inflammasome activation by intracellular LPS independent of TLR4," *Science*, vol. 341, no. 6151, pp. 1246–1249, 2013.

[39] E. Meunier, M. S. Dick, R. F. Dreier et al., "Caspase-11 activation requires lysis of pathogen-containing vacuoles by IFN-induced GTPases," *Nature*, vol. 509, no. 7500, pp. 366–370, 2014.

[40] T. Bergsbaken, S. L. Fink, and B. T. Cookson, "Pyroptosis: host cell death and inflammation," *Nature Reviews Microbiology*, vol. 7, no. 2, pp. 99–109, 2009.

[41] J. Shi, Y. Zhao, Y. Wang et al., "Inflammatory caspases are innate immune receptors for intracellular LPS," *Nature*, vol. 514, no. 7521, pp. 187–192, 2014.

[42] R. Uchiyama, S. Yonehara, and H. Tsutsui, "Fas-mediated inflammatory response in Listeria monocytogenes infection," *The Journal of Immunology*, vol. 190, no. 8, pp. 4245–4254, 2013.

[43] L. Bossaller, P.-I. Chiang, C. Schmidt-Lauber et al., "Cutting edge: FAS (CD95) mediates noncanonical IL-1β and IL-18 maturation via caspase-8 in an RIP3-independent manner," *Journal of Immunology*, vol. 189, no. 12, pp. 5508–5512, 2012.

[44] S. I. Gringhuis, T. M. Kaptein, B. A. Wevers et al., "Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1β via a noncanonical caspase-8 inflammasome," *Nature Immunology*, vol. 13, no. 3, pp. 246–254, 2012.

[45] P. Gurung, P. K. Anand, R. K. S. Malreddy et al., "FADD and caspase-8 mediate priming and activation of the canonical and noncanonical Nlrp3 inflammasomes," *Journal of Immunology*, vol. 192, no. 4, pp. 1835–1846, 2014.

[46] N. H. Philip, C. P. Dillon, A. G. Snyder et al., "Caspase-8 mediates caspase-1 processing and innate immune defense in response to bacterial blockade of NF-κB and MAPK signaling," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 20, pp. 7385–7390, 2014.

[47] E. M. Creagh, "Caspase crosstalk: integration of apoptotic and innate immune signalling pathways," *Trends in Immunology*, vol. 35, no. 12, pp. 631–640, 2014.

[48] J. M. Blander, "A long-awaited merger of the pathways mediating host defence and programmed cell death," *Nature Reviews Immunology*, vol. 14, no. 9, pp. 601–618, 2014.

[49] M. Pasparakis and P. Vandenabeele, "Necroptosis and its role in inflammation," *Nature*, vol. 517, no. 7534, pp. 311–320, 2015.

[50] S. L. Fink and B. T. Cookson, "Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells," *Infection and Immunity*, vol. 73, no. 4, pp. 1907–1916, 2005.

[51] T. Strowig, J. Henao-Mejia, E. Elinav, and R. A. Flavell, "Inflammasomes in health and disease," *Nature*, vol. 481, no. 7381, pp. 278–286, 2012.

[52] M. Lamkanfi and V. M. Dixit, "Mechanisms and functions of inflammasomes," *Cell*, vol. 157, no. 5, pp. 1013–1022, 2014.

[53] S. M. Man and T. Kanneganti, "Regulation of inflammasome activation," *Immunological Reviews*, vol. 265, no. 1, pp. 6–21, 2015.

[54] G. Pedraza-Alva, L. Pérez-Martínez, L. Valdez-Hernández, K. F. Meza-Sosa, and M. Ando-Kuri, "Negative regulation of the inflammasome: keeping inflammation under control," *Immunological Reviews*, vol. 265, no. 1, pp. 231–257, 2015.
[55] E. Latz, T. S. Xiao, and A. Stutz, “Activation and regulation of the inflammasomes,” Nature Reviews Immunology, vol. 13, no. 6, pp. 397–411, 2013.

[56] Y.-H. Youn, K. Y. Nguyen, R. W. Grant et al., “The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease,” Nature Medicine, vol. 21, pp. 263–269, 2015.

[57] R. C. Coll, A. A. Robertson, J. J. Chae et al., “A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases,” Nature Medicine, vol. 21, no. 3, pp. 248–255, 2015.

[58] B. Korkmaz, M. S. Horwitz, D. E. Jenne, and F. Gauthier, “Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases,” Pharmacological Reviews, vol. 62, no. 4, pp. 726–759, 2010.

[59] U. Meyer-Hoffert and O. Wiedow, “Neutrophil serine proteases: mediators of innate immune responses,” Current Opinion in Hematology, vol. 18, no. 1, pp. 19–24, 2011.

[60] C. Coeshott, C. Ohnemus, A. Pilyavskaya et al., “Converting enzyme-independent release of tumor necrosis factor and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 11, pp. 6261–6266, 1999.

[61] L. A. B. Joosten, M. G. Netea, G. Fantuzzi et al., “Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1β,” Arthritis and Rheumatism, vol. 60, no. 12, pp. 3651–3662, 2009.

[62] M. Guma, L. Ronacher, R. Liu-Bryan, S. Takai, M. Karin, and M. Corr, “Caspase 1-independent activation of interleukin-1β in neutrophil-predominant inflammation,” Arthritis and Rheumatism, vol. 60, no. 12, pp. 3642–3650, 2009.

[63] C. Stehlik, “Multiple interleukin-1β-converting enzymes contribute to inflammatory arthritis,” Arthritis and Rheumatism, vol. 60, no. 12, pp. 3524–3530, 2009.

[64] S. Sugawara, A. Uehara, T. Nochi et al., “Neutrophil proteinase 3-mediated induction of bioactive IL-18 secretion by human oral epithelial cells,” Journal of Immunology, vol. 167, no. 11, pp. 6568–6575, 2001.

[65] S. Bae, T. Kang, J. Hong et al., “Contradictory functions (activation/termination) of neutrophil proteinase 3 enzyme (PR3) in interleukin-33 biological activity,” The Journal of Biological Chemistry, vol. 287, no. 11, pp. 8205–8213, 2012.

[66] Y. Motoo, K. Tokime, K. Yamanaka et al., “Human mast cell chymase cleaves pro-IL-18 and generates a novel and biologically active IL-18 fragment,” Journal of Immunology, vol. 177, no. 12, pp. 8315–8319, 2006.

[67] H. Konishi, H. Tsutsui, T. Murakami et al., “IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 17, pp. 11340–11345, 2002.

[68] H. Imai, K. Yasuda, Y. Sakaguchi et al., “Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 34, pp. 13921–13926, 2013.

[69] K. Nakanishi, T. Yoshimoto, H. Tsutsui, and H. Okamura, “Interleukin-18 regulates both Th1 and Th2 responses,” Annual Review of Immunology, vol. 19, pp. 423–474, 2001.

[70] T. Yoshimoto and K. Matsushita, “Innate-type and acquired-type allergy regulated by IL-33,” Allergology International, vol. 63, supplement 1, pp. 3–11, 2014.

[71] I. S. Afonina, S. P. Cullen, and S. J. Martin, “Cytotoxic and noncytotoxic roles of the CTL/NK protease granzyme B,” Immunological Reviews, vol. 235, no. 1, pp. 105–116, 2010.

[72] Y. Motoo, K. Yamanaka, K. Tokime et al., “Granzyme B is a novel interleukin-18 converting enzyme,” Journal of Dermatological Science, vol. 59, no. 2, pp. 129–135, 2010.

[73] C. Herzog, R. S. Haun, V. Kaushal, P. R. Mayeux, S. V. Shah, and G. P. Kaushal, “Meprin A and meprin α generate biologically functional IL-1β from pro-IL-1β,” Biochemical and Biophysical Research Communications, vol. 379, no. 4, pp. 904–908, 2009.

[74] S. Banerjee and J. S. Bond, “Proinflammatory IL-1β is activated by meprin β in vitro and in vivo in intestinal inflammation,” Journal of Biological Chemistry, vol. 283, no. 46, pp. 31371–31377, 2008.

[75] E. E. Sterchi, W. Stöcker, and J. S. Bond, “Meprins, membrane-bound and secreted astacin metalloproteinases,” Molecular Aspects of Medicine, vol. 29, no. 5, pp. 309–328, 2009.

[76] C. Broder and C. Becker-Pauly, “The metalloproteinases meprin α and meprin β: unique enzymes in inflammation, neurodegeneration, cancer and fibrosis,” Biochemical Journal, vol. 450, no. 2, pp. 253–264, 2013.

[77] J. R. Lukens, J. M. Gross, C. Calabrese et al., “Critical role for inflammasome-independent IL-1β production in osteomyelitis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 3, pp. 1066–1071, 2014.

[78] S. L. Cassell, J. R. Janczy, X. Bing et al., “Inflammasome-independent IL-1β mediates autoinflammatory disease in Pstpip2-deficient mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 3, pp. 1072–1077, 2014.

[79] P. J. Ferguson, X. Bing, M. A. Vasef et al., “A missense mutation in pstpip2 is associated with the murine autoinflammatory disorder chronic multifocal osteomyelitis,” Bone, vol. 38, no. 1, pp. 41–47, 2006.

[80] J. Grosse, V. Chitu, A. Marquardt et al., “Mutation of mouse Mapp/Pstpip2 causes a macrophage autoinflammatory disease,” Blood, vol. 107, no. 8, pp. 3350–3358, 2006.

[81] V. Chifu, P. J. Ferguson, R. De Brujin et al., “Primed innate immunity leads to autoimmune disease in Pstpip2-deficient cmo mice,” Blood, vol. 114, no. 12, pp. 2497–2505, 2009.

[82] J. R. Lukens, P. Gurung, P. Vogel et al., “Dietary modulation of the microbiome affects autoinflammatory disease,” Nature, vol. 516, no. 7530, pp. 246–249, 2014.

[83] M. G. Netea, F. L. van de Veerdonk, J. W. van der Meer, C. A. Dinarello, and L. A. Joosten, “Inflammasome-independent regulation of IL-1 family cytokines,” Annual Review of Immunology, vol. 33, no. 1, pp. 49–77, 2015.

[84] K. L. Rock, E. Latz, F. Ontiveros, and H. Kono, “The sterile inflammatory response,” Annual Review of Immunology, vol. 28, pp. 321–342, 2010.

[85] S. Freigang, F. Ampenberger, A. Weiss et al., “Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent IL-1α and sterile vascular inflammation in atherosclerosis,” Nature Immunology, vol. 14, no. 10, pp. 1045–1053, 2013.

[86] J. Lugrin, R. Parapanov, N. Rosenblatt-Velin et al., “Cutting edge: IL-1α is a crucial danger signal triggering acute myocardial inflammation during myocardial infarction,” Journal of Immunology, vol. 194, no. 2, pp. 499–503, 2015.

[87] Y. Berda-Haddad, S. Robert, P. Salers et al., “Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by...
interleukin-1α, Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 51, pp. 20684–20689, 2011.

[88] H. G. Hutton, H. R. Summersgill, M. E. Edye, N. J. Rothwell, and D. Brough, “Release of interleukin-1α or interleukin-1β depends on mechanism of cell death,” The Journal of Biological Chemistry, vol. 289, no. 23, pp. 15942–15950, 2014.

[89] K. Moriwaki and K. F. Chan, “RIP3: a molecular switch for necrosis and inflammation,” Genes and Development, vol. 27, no. 15, pp. 1640–1649, 2013.

[90] J. M. Murphy, P. E. Czabotar, J. M. Hildebrand et al., “The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism,” Immunity, vol. 39, no. 3, pp. 443–453, 2013.

[91] J. Wu, Z. Huang, L. Ren et al., “Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis,” Cell Research, vol. 23, no. 8, pp. 994–1006, 2013.

[92] H. Wang, L. Sun, L. Su et al., “Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3,” Molecular Cell, vol. 54, no. 1, pp. 133–146, 2014.

[93] X. Chen, W. Li, J. Ren et al., “Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death,” Cell Research, vol. 24, no. 1, pp. 105–121, 2014.

[94] D. L. Castner, I. Aksentijevich, and R. Goldbach-Mansky, “Autoinflammatory disease reloaded: a clinical perspective,” Cell, vol. 140, no. 6, pp. 784–790, 2010.

[95] I. Aksentijevich, S. L. Masters, P. I. Ferguson et al., “An autoinflammatory disease with deficiency of the interleukin-1 receptor antagonist,” The New England Journal of Medicine, vol. 360, no. 23, pp. 2426–2437, 2009.

[96] S. Reddy, S. Jia, R. Geoffrey et al., “An autoinflammatory disease due to homozygous deletion of the IL1RN locus,” The New England Journal of Medicine, vol. 360, no. 23, pp. 2438–2444, 2009.

[97] A. de Jesus, S. W. Canna, Y. Liu, and R. Goldbach-Mansky, “Molecular mechanisms in genetically defined autoinflammatory diseases: disorders of amplified danger signaling,” Annual Review of Immunology, vol. 33, no. 1, pp. 823–874, 2015.

[98] K. Maedler, P. Sergeev, F. Ris et al., “Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets,” Journal of Clinical Investigation, vol. 110, no. 6, pp. 851–860, 2002.

[99] M. Y. Donath and S. E. Shoelson, “Type 2 diabetes as an inflammatory disease,” Nature Reviews Immunology, vol. 11, no. 2, pp. 98–107, 2011.

[100] R. W. Grant and V. D. Dixit, “Mechanisms of disease: inflammatory activation and the development of type 2 diabetes,” Frontiers in Immunology, vol. 4, article 50, 2013.

[101] C. M. Larsen, M. Faulenbach, A. Vaag et al., “Interleukin-1 receptor antagonist in type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 356, no. 15, pp. 1517–1526, 2007.

[102] K. Yasuda, T. Muto, T. Kawagoe et al., “Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode–infected mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 9, pp. 3451–3456, 2012.

[103] S. Reddy, S. Jia, R. Geoffrey et al., “An autoinflammatory disease due to homozygous deletion of the IL1RN locus,” The New England Journal of Medicine, vol. 360, no. 23, pp. 2438–2444, 2009.

[104] M. J. Gold, F. Antignano, T. Y. F. Halim et al., “Group 2 innate lymphoid cells facilitate sensitization to local, but not systemic, Th2-inducing allergen exposures,” Journal of Allergy and Clinical Immunology, vol. 133, no. 4, pp. 425–435, 2014.

[105] I. Martinez-Gonzalez, C. A. Steer, and F. Takei, “Lung ILC2s link innate and adaptive responses in allergic inflammation,” Trends in Immunology, vol. 36, no. 3, pp. 189–195, 2015.

[106] R. Saluja, M. E. Ketelaar, T. Hawro, M. K. Church, M. Maurer, and M. C. Nawijn, “The role of the IL-33/IL-1RL1 axis in mast cell and basophil activation in allergic disorders,” Molecular Immunology, vol. 63, no. 1, pp. 80–85, 2015.

[107] D. E. Byers, J. Alexander-Brett, A. C. Patel et al., “Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease,” Journal of Clinical Investigation, vol. 123, no. 9, pp. 3967–3982, 2013.

[108] T. A. Wynn, “IL-13 effector functions,” Annual Review of Immunology, vol. 21, pp. 425–465, 2003.

[109] T. A. Wynn and T. R. Ramalingam, “Mechanisms of fibrosis: therapeutic translation for fibrotic disease,” Nature Medicine, vol. 18, no. 7, pp. 1028–1040, 2012.

[110] T. A. Wynn, A. Chawla, and J. W. Pollard, “Macrophage biology in development, homeostasis and disease,” Nature, vol. 496, no. 7446, pp. 445–455, 2013.

[111] C. J. Oliphant, Y. Y. Hwang, J. A. Walker et al., “MHCII-mediated dialog between group 2 innate lymphoid cells and CD4+ T cells potentiates type 2 immunity and promotes parasitic helminth expulsion,” Immunity, vol. 41, no. 2, pp. 283–295, 2014.

[112] K. Yasuda, M. Matsumoto, and K. Nakanishi, “Importance of both innate immunity and acquired immunity for rapid expulsion of S. venezuelensis,” Frontiers in Immunology, vol. 5, article 118, Article ID Article 118, 2014.

[113] D. Arts and H. Spits, “The biology of innate lymphoid cells,” Nature, vol. 517, no. 7534, pp. 293–301, 2015.

[114] A.-G. Besnard, R. Guabiraba, W. Niedbala et al., “IL-33-mediated protection against experimental cerebral malaria is linked to induction of type 2 innate lymphoid cells, M2 macrophages and regulatory T cells,” PLoS Pathogens, vol. 11, no. 2, Article ID e1004607, 2015.

[115] B. S. Kim, E. D. T. Wojno, and D. Arts, “Innate lymphoid cells and allergic inflammation,” Current Opinion in Immunology, vol. 25, no. 6, pp. 738–744, 2013.

[116] P. Licona-Limón, L. K. Kim, N. W. Palm, and R. A. Flavell, “TH2, allergy and group 2 innate lymphoid cells,” Nature Immunology, vol. 14, no. 6, pp. 536–542, 2013.

[117] T. Y. F. Halim, C. A. Steer, L. Mathé et al., “Group 2 innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic lung inflammation,” Immunity, vol. 40, no. 3, pp. 425–435, 2014.

[118] T. A. Wynn and T. R. Ramalingam, “Mechanisms of fibrosis: therapeutic translation for fibrotic disease,” Nature Medicine, vol. 18, no. 7, pp. 1028–1040, 2012.

[119] T. A. Wynn, A. Chawla, and J. W. Pollard, “Macrophage biology in development, homeostasis and disease,” Nature, vol. 496, no. 7446, pp. 445–455, 2013.

[120] W. C. Gause, T. A. Wynn, and J. E. Allen, “Type 2 immunity and wound healing: evolutionary refinement of adaptive immunity by helminths,” Nature Reviews Immunology, vol. 13, no. 8, pp. 687–614, 2013.
D. Li, R. Bataller, "Alcoholic liver disease: pathogenesis and new therapeutic targets," *Gastroenterology*, vol. 141, no. 5, pp. 1572–1585, 2011.

M. Manetti, L. Ibba-Manneschi, V. Liakousi et al., "The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis," *Annals of the Rheumatic Diseases*, vol. 69, no. 3, pp. 598–605, 2010.

K. Yanaba, A. Yoshizaki, Y. Asano, T. Kadono, and S. Sato, "Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis," *Clinical Rheumatology*, vol. 30, no. 6, pp. 825–830, 2011.

A. L. Rankin, J. B. Mumm, E. Murphy et al., "IL-33 induces IL-13-dependent cutaneous fibrosis," *Journal of Immunology*, vol. 184, no. 3, pp. 1526–1535, 2010.

I. G. Luzina, P. Kopach, V. Lockatell et al., "Interleukin–33 potentiates bleomycin-induced lung injury," *American Journal of Respiratory Cell and Molecular Biology*, vol. 49, no. 6, pp. 999–1008, 2013.

D. Li, R. Guabiraba, A.-G. Besnard et al., "IL-33 promotes ST2-dependent lung fibrosis by the induction of alternatively activated macrophages and innate lymphoid cells in mice," *Journal of Allergy and Clinical Immunology*, vol. 134, no. 6, pp. 1422–1432, 2014.

K. Nakanishi, T. Yoshimoto, H. Tsutsui, and H. Okamura, "Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu," *Cytokine and Growth Factor Reviews*, vol. 12, no. 1, pp. 53–72, 2001.

K. Nakanishi, H. Tsutsui, and T. Yoshimoto, "Importance of IL-18-induced super Th1 cells for the development of allergic inflammation," *Allergology International*, vol. 59, no. 2, pp. 137–141, 2010.

H. Tsutsui, T. Yoshimoto, N. Hayashi, H. Mizutani, and K. Nakanishi, "Induction of allergic inflammation by interleukin-18 in experimental animal models," *Immunological Reviews*, vol. 202, pp. 115–138, 2004.

H. Tsutsui, K. Matsui, H. Okamura, and K. Nakanishi, "Pathophysiologic roles of interleukin-18 in inflammatory liver diseases," *Immunological Reviews*, vol. 174, pp. 192–209, 2000.

E. Seki, H. Tsutsui, N. M. Tsuji et al., "Critical roles of myeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance of Listeria monocytogenes in mice," *Journal of Immunology*, vol. 169, no. 7, pp. 3863–3868, 2002.

T. Yoshimoto, B. Min, T. Sugimoto et al., "Nonredundant roles for CD1d-restricted natural killer T cells and conventional CD4+ T cells in the induction of immunoglobulin E antibodies in response to interleukin 18 treatment of mice," *Journal of Experimental Medicine*, vol. 197, no. 8, pp. 997–1005, 2003.

Y. Sasaki, T. Yoshimoto, H. Maruyama et al., "IL-18 with IL-2 protects against Strongyloides venezuelensis infection by activating mucosal mast cell-dependent type 2 innate immunity," *The Journal of Experimental Medicine*, vol. 202, no. 5, pp. 607–616, 2005.

T. Sugimoto, Y. Ishikawa, T. Yoshimoto, B. Hayashi, J. Fujimoto, and K. Nakanishi, "Interleukin 18 acts on memory T helper cells type 1 to induce airway inflammation and hyperresponsiveness in a naive host mouse," *The Journal of Experimental Medicine*, vol. 199, no. 4, pp. 535–545, 2004.

M. Terada, H. Tsutsui, Y. Imai et al., "Contribution of IL-18 to atopic-dermatitis-like skin inflammation induced by *Staphylococcus aureus* product in mice," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 23, pp. 8816–8821, 2006.

N. Hayashi, T. Yoshimoto, K. Izuhara, K. Matsui, T. Tanaka, and K. Nakanishi, "T helper 1 cells stimulated with ovalbumin and IL-18 induce airway hyperresponsiveness and lung fibrosis by IFN-γ and IL-13 production," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 37, pp. 14765–14770, 2007.

H. Tsutsui and K. Nakanishi, "Immunotherapeutic applications of IL-18," *Immunotherapy*, vol. 4, no. 12, pp. 1883–1894, 2012.

M. G. Netea, L. A. B. Joosten, E. Lewis et al., "Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance," *Nature Medicine*, vol. 12, no. 6, pp. 650–656, 2006.

Y. Moriwaki, T. Yamamoto, Y. Shibutani et al., "Elevated levels of interleukin-18 and tumor necrosis factor-α in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy," *Metabolism: Clinical and Experimental*, vol. 52, no. 5, pp. 605–608, 2003.

G. Pan, P. Risser, W. Mao et al., "IL-1H, an interleukin 1-related protein that binds IL-18 receptor/IL-1Rrp," *Cytokine*, vol. 13, no. 1, pp. 1–7, 2001.

M. F. Nold, C. A. Nold-Petry, J. A. Zepp, B. E. Palmer, P. Butler, and C. A. Dinarello, "IL-37 is a fundamental inhibitor of innate immunity," *Nature Immunology*, vol. 11, no. 11, pp. 1014–1022, 2010.

E. N. McNamee, J. C. Masterson, P. Jedlicka et al., "Interleukin 37 expression protects mice from colitis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 108, no. 40, pp. 16711–16716, 2011.

Z. Ye, C. Wang, A. Kijlstra, X. Zhou, and P. Yang, "A possible role for interleukin 37 in the pathogenesis of Behcet's disease," *Current Molecular Medicine*, vol. 14, no. 4, pp. 535–542, 2014.

L. Lunding, S. Webering, C. Vock et al., "IL-37 requires IL-18Rα and SIGIRR/IL-1R8 to diminish allergic airway inflammation in mice," *Allergy*, vol. 70, no. 4, pp. 366–373, 2015.

C. A. Nold-Petry, C. Y. Lo, I. Rudloff et al., "IL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transduction," *Nature Immunology*, vol. 16, no. 4, pp. 354–365, 2015.

E. Dunn, J. E. Sims, M. J. H. Nicklin, and L. A. J. O'Neill, "Annotating genes with potential roles in the immune system: six new members of the IL-1 family," *Trends in Immunology*, vol. 22, no. 10, pp. 533–536, 2001.

J. E. Towne, K. E. Garka, B. R. Renshaw, G. D. Virca, and J. E. Sims, "Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL-1RAcp to activate the pathway leading to NF-κB and MAPKs," *Journal of Biological Chemistry*, vol. 279, no. 14, pp. 13677–13688, 2004.

H. Blumberg, H. Dinh, E. S. Trueblood et al., "Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation," *The Journal of Experimental Medicine*, vol. 204, no. 11, pp. 2603–2614, 2007.

H. Blumberg, H. Dinh, C. Dean Jr. et al., "IL-1RL2 and its ligands contribute to the cytokine network in psoriasis," *The Journal of Immunology*, vol. 185, no. 7, pp. 4354–4362, 2010.

L. Tortola, E. Rosenwald, B. Abel et al., "Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk," *Journal of Clinical Investigation*, vol. 122, no. 11, pp. 3965–3976, 2012.
[151] S. Marrakchi, P. Guigue, B. R. Renshaw et al., “Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis,” The New England Journal of Medicine, vol. 365, no. 7, pp. 620–628, 2011.

[152] A. Onoufriadis, M. A. Simpson, A. E. Pink et al., “Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis,” American Journal of Human Genetics, vol. 89, no. 3, pp. 432–437, 2011.

[153] Y. Renert-Yuval, L. Horev, S. Babay et al., “IL-36RN mutation causing generalized pustular psoriasis in a Palestinian patient,” International Journal of Dermatology, vol. 53, no. 7, pp. 866–868, 2014.

[154] J. E. Towne and J. E. Sim, “IL-36 in psoriasis,” Current Opinion in Pharmacology, vol. 12, no. 4, pp. 486–490, 2012.

[155] F. L. van de Veerdonk, A. K. Stoeckman, G. Wu et al., “IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 8, pp. 3001–3005, 2012.

[156] A. A. Negash and M. Gale Jr., “Hepatitis regulation by the inflammasome signaling pathway,” Immunological Reviews, vol. 265, no. 1, pp. 143–155, 2015.

[157] K. Watashi, G. Liang, M. Iwamoto et al., “Interleukin-1 and tumor necrosis factor-α trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID),” The Journal of Biological Chemistry, vol. 288, no. 44, pp. 37175–37127, 2013.

[158] S. Jegasantha, S. H. Ahn, N. Skinner et al., “Downregulation of interleukin-18-mediated cell signaling and interferon gamma expression by the hepatitis B virus e antigen,” Journal of Virology, vol. 88, no. 18, pp. 10412–10420, 2014.

[159] K. Kaneda, N. Kurioka, S. Seki, K. Wake, and S. Yamamoto, “Pit cell-hepatocyte contact in autoimmune hepatitis,” Hepatology, vol. 4, no. 5, pp. 955–958, 1984.

[160] S. M. Horner and M. Gale Jr., “Regulation of hepatic innate immunity by hepatitis C virus,” Nature Medicine, vol. 19, no. 7, pp. 879–888, 2013.

[161] A. Sharma, A. Chakraborti, A. Das, R. K. Dhiman, and Y. Chawla, “Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis,” Immunology, vol. 128, no. 1, pp. e514−e522, 2009.

[162] S. Shrivastava, A. Mukherjee, R. Ray, and R. B. Raya, “Hepatitis C virus induces interleukin-1β (IL-1β)/IL-18 in circulatory and resident liver macrophages,” Journal of Virology, vol. 87, no. 22, pp. 12284–12290, 2013.

[163] A. A. Negash, H. J. Ramos, N. Crochet et al., “IL-1β production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease,” PLoS Pathogens, vol. 9, no. 4, Article ID e1003330, 2013.

[164] M. A. Chattergoon, R. Latanich, J. Quinn et al., “HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type I interferon,” PLoS Pathogens, vol. 10, no. 5, Article ID e1004082, 2014.

[165] T. Luedde, N. Kaplowitz, and R. F. Schwabe, “Cell death and cell death responses in liver disease: mechanisms and clinical relevance,” Gastroenterology, vol. 147, no. 4, pp. 765–783, 2014.

[166] A. Ramachandran, M. R. Mcgill, Y. Xie, H.-M. Ni, W.-X. Ding, and H. Jaeschke, “Receptor interacting protein kinase 3 is a critical early mediator of acetaminophen-induced hepatocyte necrosis in mice,” Hepatology, vol. 58, no. 6, pp. 2099–2108, 2013.

[167] J.-X. Li, J.-M. Feng, Y. Wang et al., “The B-RafV600E inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury,” Cell Death and Disease, vol. 5, no. 6, Article ID e1278, 2014.

[168] S. Roychowdhury, M. R. Mcmullen, S. G. Pisano, X. Liu, and L. E. Nagy, “Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury,” Hepatology, vol. 57, no. 5, pp. 1773–1783, 2013.

[169] S. Gao, K. Andreeva, and N. G. F. Cooper, “Ischemia-reperfusion injury of the retina is linked to necroptosis via the ERK1/2-RIP3 pathway,” Molecular Vision, vol. 20, pp. 1374–1387, 2014.

[170] A. Linkermann, J. H. Bräsen, M. Darding et al., “Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 29, pp. 12024–12029, 2013.

[171] J. Gautheron, M. Vucur, F. Reisinger et al., “A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis,” EMBO Molecular Medicine, vol. 6, no. 8, pp. 1062–1074, 2014.

[172] H. Wen, D. Gris, Y. Lei et al., “Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling,” Nature Immunology, vol. 12, no. 5, pp. 408–415, 2011.

[173] R. Stienstra, J. A. van Diepen, C. J. Tack et al., “Inflammasome is a central player in the induction of obesity and insulin resistance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 37, pp. 15324–15329, 2011.

[174] K. Miura, Y. Kodama, S. Inokuchi et al., “Toll-like receptor 9 promotes steatohepatitis by induction of Interleukin-1β in mice,” Gastroenterology, vol. 139, no. 1, pp. 323–334, 2010.

[175] K. Miura, L. Yang, N. van Rooijen, H. Ohnishi, and E. Seki, “Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 302, no. 11, pp. G1310–G1321, 2012.

[176] T. Csak, M. Ganz, J. Pespisa, K. Kodys, A. Dolganvic, and G. Szabo, “Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells,” Hepatology, vol. 54, no. 1, pp. 133–144, 2011.

[177] E. J. Barreiro, S. Holod, P. V. Finocchietto et al., “The pan-caspase inhibitor Emricasan (IDN–6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis,” Liver International, vol. 35, no. 3, pp. 953–966, 2015.

[178] J. Henao-Mejia, E. Elinav, C. Jin et al., “Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity,” Nature, vol. 482, no. 7384, pp. 179–185, 2012.

[179] J. Henao-Mejia, E. Elinav, C. A. Thaiss, and R. A. Flavell, “Inflammasomes and metabolic disease,” Annual Review of Physiology, vol. 76, pp. 57–78, 2014.

[180] A. B. Imaeda, A. Watanabe, M. A. Sohail et al., “Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome,” Journal of Clinical Investigation, vol. 119, no. 2, pp. 305–314, 2009.

[181] Z. M. Bamboat, V. P. Balachandran, L. M. Ocuin, H. Obaid, G. Plitas, and R. P. DeMatteo, “Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury,” Hepatology, vol. 51, no. 2, pp. 621–632, 2010.

[182] R. F. van Golen, T. M. van Gulik, and M. Heger, “The sterile immune response during hepatic ischemia-reperfusion,” Cytokine & Growth Factor Reviews, vol. 23, no. 3, pp. 69–84, 2012.
K. R. Karlmark, R. Weiskirchen, H. W. Zimmermann et al., "Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis," *Hepatology*, vol. 50, no. 1, pp. 261–274, 2009.

P. Ramachandran, A. Pellicoro, M. A. Vernon et al., "Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 109, no. 46, pp. E3186–E3195, 2012.

E. Seki and D. A. Brenner, "Recent advancement of molecular mechanisms of liver fibrosis," *Journal of Hepato-Biliary-Pancreatic Sciences*, vol. 22, no. 7, pp. 512–518, 2015.

A. Pellicoro, P. Ramachandran, J. P. Iredale, and J. A. Fallowfield, "Liver fibrosis and repair: immune regulation of wound healing in a solid organ," *Nature Reviews Immunology*, vol. 14, no. 3, pp. 181–194, 2014.

G. Wick, C. Grundtman, C. Mayer et al., "The immunology of fibrosis," *Annual Review of Immunology*, vol. 31, pp. 107–135, 2013.

T. A. Wynn, "Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases," *The Journal of Clinical Investigation*, vol. 117, no. 3, pp. 524–529, 2007.

P. Marvie, M. Lisbonne, A. L’Helgoualc’h et al., "Interleukin-33 overexpression is associated with liver fibrosis in mice and humans," *Journal of Cellular and Molecular Medicine*, vol. 14, no. 6, pp. 1726–1739, 2010.

T. Mcchedlidze, M. Waldner, S. Zopf et al., "Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis," *Immunity*, vol. 39, no. 2, pp. 357–371, 2013.

K. Moro, T. Yamada, M. Tanabe et al., "Innate production of Th2 cytokines by adipose tissue-associated c-Kit+Sca-1+ lymphoid cells," *Nature*, vol. 463, no. 7280, pp. 540–544, 2010.

J. Kang and N. Malhotra, "Transcription factor networks directing the development, function, and evolution of innate lymphoid effectors," *Annual Review of Immunology*, vol. 33, no. 1, pp. 505–538, 2015.

G. Eberl, M. Colonna, J. P. Di Santo, and A. N. McKenzie, "Innate lymphoid cells: a new paradigm in immunology," *Science*, vol. 348, no. 6237, Article ID aaa6566, 2015.

J. Li, N. Razumilava, G. J. Gores et al., "Biliary repair and carcinogenesis are mediated by IL-33-dependent cholangiocyte proliferation," *The Journal of Clinical Investigation*, vol. 124, pp. 3241–3251, 2014.

J. Li, K. Bessho, P. Shivakumar et al., "Th2 signals induce epithelial injury in mice and are compatible with the biliary atresia phenotype," *Journal of Clinical Investigation*, vol. 121, no. 11, pp. 4244–4256, 2011.

D. Yamada, S. Rizvi, N. Razumilava et al., "IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism," *Hepatology*, vol. 61, no. 5, pp. 1627–1642, 2015.

T. Suganami and Y. Ogawa, "Adipose tissue macrophages: their role in adipose tissue remodeling," *Journal of Leukocyte Biology*, vol. 88, no. 1, pp. 33–39, 2010.

J. McNelis and J. Olefsky, "Macrophages, immunity, and metabolic disease," *Immunity*, vol. 41, no. 1, pp. 36–48, 2014.

X. Chen, Y. Wu, and L. Wang, "Fat-resident Tregs: an emerging guard protecting from obesity-associated metabolic disorders," *Obesity Reviews*, vol. 14, no. 7, pp. 568–578, 2013.

A. M. Miller, D. L. Asquith, A. J. Hueber et al., "Interleukin-33 induces protective effects in adipose tissue inflammation during obesity in mice," *Circulation Research*, vol. 107, no. 5, pp. 650–658, 2010.

J. M. Han, D. Wu, H. C. Denroche, Y. Yao, C. B. Verchere, and M. K. Levings, "IL-33 reverses an obesity-induced deficit in visceral adipose tissue ST2+ T regulatory cells and ameliorates adipose tissue inflammation and insulin resistance," *The Journal of Immunology*, vol. 194, no. 10, pp. 4777–4783, 2015.

D. Kolodin, N. van Panhuys, C. Li et al., "Antigen- and cytokine-driven accumulation of regulatory T cells in visceral adipose tissue of lean mice," *Cell Metabolism*, vol. 21, no. 4, pp. 543–557, 2015.

A. Vasanthakumar, K. Moro, A. Xin et al., "The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue–resident regulatory T cells," *Nature Immunology*, vol. 16, pp. 276–285, 2015.

A. B. Molofsky, J. C. Nussbaum, H.-E. Liang et al., "Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages," *The Journal of Experimental Medicine*, vol. 210, no. 3, pp. 535–549, 2013.

Y. Qiu, K. D. Nguyen, J. I. Odeggaard et al., "Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat," *Cell*, vol. 157, no. 6, pp. 1292–1308, 2014.

J. R. Brestoff, B. S. Kim, S. A. Saenz et al., "Group 2 innate lymphoid cells promote beigeing of white adipose tissue and limit obesity," *Nature*, vol. 519, no. 7542, pp. 242–246, 2014.

M.-W. Lee, J. I. Odeggaard, L. Mukundan et al., "Activated type 2 innate lymphoid cells regulate beige fat biogenesis," *Cell*, vol. 160, no. 1–2, pp. 74–87, 2015.

T. A. Doherty, "At the bench: understanding group 2 innate lymphoid cells in disease," *Journal of Leukocyte Biology*, vol. 97, no. 3, pp. 455–467, 2015.

R. Stokes Peebles Jr., "At the bedside: the emergence of group 2 innate lymphoid cells in human disease," *Journal of Leukocyte Biology*, vol. 97, no. 3, pp. 469–475, 2015.

J. Suez, T. Korem, D. Zeevi et al., "Artificial sweeteners induce glucose intolerance by altering the gut microbiota," *Nature*, vol. 514, no. 7521, pp. 181–186, 2014.

B. Chassaing, O. Koren, J. K. Goodrich et al., "Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome," *Nature*, vol. 519, no. 7541, pp. 92–96, 2015.

M. Saijish and P. Schimmel, "A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol," *Nature*, vol. 519, pp. 370–373, 2015.

Y. Tang, "Curcumin targets multiple pathways to halt hepatic stellate cell activation: updated mechanisms in vitro and in vivo," *Digestive Diseases and Sciences*, vol. 60, no. 6, pp. 1554–1564, 2015.

I. I. Severina, F. F. Severin, G. A. Korshunova et al., "In search of novel highly active mitochondria-targeted antioxidants: thymoquinone and its cationic derivatives," *FEBS Letters*, vol. 587, no. 13, pp. 2018–2024, 2013.